


Aimovig - Injection training video - HCP

Prescribing information

Image



Image



Aimovig injection training video



This video is intended for patients who have been prescribed Aimovig (erenumab) for migraines. Aimovig is used to prevent migraine in adults who have at least 4 migraine days per month when starting treatment with Aimovig.

Please read the patient information leaflet for Aimovig 70 mg or 140 mg pre-filled pen provided with your medicine carefully, as it contains important additional information about what you need to know before you start treatment. This video does not replace the instructions and important additional information in the patient information leaflet.

Reporting of side effects.

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. You can report side-effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side-effects you can help provide more information on the safety of your medication.

Please see www.mhra.gov.uk/yellowcard for instructions on how to report side effects. This video is developed and funded by Novartis Pharmaceuticals UK.



UK | January 2024 | 400906



UK | January 2025 | FA-11344093

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

https://www.pro.novartis.com/uk-en/medicines/neuroscience/aimovig/dosing/injection-training-video